Applications of Boc-Tyr(2,6-Di-Cl-Bzl)-OH in Industrial Manufacturing

Boc-Tyr(2,6-Di-Cl-Bzl)-OH, as an advanced protected amino acid derivative, supports multiple specialty chemical and pharmaceutical sectors requiring controlled peptide synthesis and high-purity intermediates. Below are real-world industrial application areas, each reflecting actual process demands and final end uses.

1. Peptide Active Pharmaceutical Ingredient (API) Manufacturing

Our Boc-Tyr(2,6-Di-Cl-Bzl)-OH serves as a critical building block for GMP-grade peptide APIs, where controlled protection and chlorinated side chains enhance target selectivity and process reliability. Major pharmaceutical plants incorporate this raw material during solid-phase and solution-phase peptide syntheses, particularly when synthesizing analogues such as peptide hormones, antitumor agents, or modified immunomodulators. Manufacturers require consistently low levels of residual chloride and prevention of racemization, achieved through in-line QC, making this amino acid derivative integral to quality-driven API production.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP <797>, <823> regulations for parenteral drugs
• European Pharmacopoeia 10.0, relevant peptide monograph requirements
• FDA 21 CFR Part 210 & 211 for finished pharmaceuticals

Typical usage ratio

• Ranges from 0.08 to 0.15 mole per mole total amino acids in target peptide chain, depending on presence of multiple modified tyrosine residues
• Adjustment based on sequence length, site-specific modification, and stepwise yield optimization

Downstream process integration

• Direct loading onto resin for Fmoc or Boc solid-phase peptide synthesis (SPPS)
• In-situ deprotection followed by coupling in liquid-phase multi-step reactions
• Integrated into automated synthesizer cycles for GMP batch production
• Critical input for regulated batch records entered at sequence-specific coupling steps

Final product types

• Synthetic peptide-based APIs (e.g., GnRH analogues, peptide vaccines, anticancer conjugates)
• Parenteral peptides supplied in lyophilized or solution form
• Custom research peptides for clinical trial supply
• Injectable specialty pharmaceuticals

2. Biotech Custom Peptide Synthesis Services

Contract peptide manufacturers and biotechnology CROs utilize our amino acid derivative in high-throughput, client-specified projects involving sequence-specific modification or unusual protection patterns. Automated synthesizers at peptide production facilities rely on the product for achieving demanding purity, low endotoxin, and compatibility with downstream modifications like fluorescent or drug conjugation. As customer requirements grow for sequence fidelity and process documentation, our material meets tight audit and traceability needs in ISO 9001:2015 and ISO 13485:2016 environments.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems
• ISO 13485:2016 for medical devices and peptides used in diagnostic kits
• Customer-validated in-house QC protocols, NMR/LC-MS spec sheets
• RoHS and REACH where peptide products enter regulated territories

Typical usage ratio

• 0.05–0.12 mol/mol in client-specified peptide chains
• Quantity scaled according to order batch size (typically 10 mg to 5 g per custom lot)

Downstream process integration

• Synthesis step in programmable SPPS platforms (microwave or flow reactors)
• Intermediate for attachment of functional probe molecules
• Entry phase for incorporating non-natural amino acids in hybrid peptides
• Verification by on-line HPLC and MALDI-TOF analysis

Final product types

• Custom peptides for biomedical research
• Diagnostic and imaging probe conjugates
• Screening libraries for drug discovery
• Peptide reference standards for analytical laboratories

3. Pharmaceutical Impurity Reference Standard Production

Quality control laboratories and reference standard providers use Boc-Tyr(2,6-Di-Cl-Bzl)-OH as an essential starting material in synthesizing process impurities and degradation products required for finished pharmaceutical product validation. These reference standards underpin regulatory filings, ensuring product safety and stability data. By using high-purity, well-characterized starting materials, manufacturers can reliably prepare structurally validated impurity signatures demanded by pharmacopoeial documentation.

Industry compliance standards

• USP General Chapters <621> (Chromatography) and <1225> (Validation)
• European Pharmacopoeia 10.0, reference standards sections
• Certificate of Analysis (CoA) and traceability documentation for all reference batches
• WHO Good Laboratory Practice (GLP) for QA laboratories

Typical usage ratio

• 0.03–0.1 mol, variable depending on impurity synthesis yield and reporting threshold
• Batch amounts typically range from 250 mg to 10 g per impurity reference lot

Downstream process integration

• First step in multistep synthesis of process impurities
• Controlled protection/deprotection to mirror main pipeline drug synthesis
• Used in scale-up studies for stress-testing peptide drug stability
• Integrated with analytical validation prior to release

Final product types

• Pharmaceutical impurity reference standards for HPLC and GC analysis
• Degradation markers for API and formulated product stability testing
• Characterized peptide fragments for regulatory submission
• USP/EP compendial impurity samples

4. Advanced Peptide Drug Conjugate (PDC) Synthesis

This amino acid derivative finds specialized use in the pharmaceutical sector for the manufacture of certain peptide drug conjugates, where the dichlorobenzyl functionality supports targeted drug delivery mechanisms. Custom synthesis teams integrate this building block to attach cytotoxic payloads or imaging agents through precision linkage strategies, requiring stringent control of side chain reactivity and peptide backbone integrity through multi-step, multi-solvent processes. Documentation of each reagent addition and side-chain deprotection event meets GMP-level expectations in regulated plants.

Industry compliance standards

• US FDA cGMP regulations 21 CFR Part 210 & 211
• ICH Q11 Development and Manufacture of Drug Substances
• EMA Guidelines on quality of biological active substances
• Internal QA/QC validated per customer drug master files (DMFs)

Typical usage ratio

• Custom ratios from 0.09 to 0.22 mol/mol, based on required number of conjugation sites
• Fine-tuned according to payload stoichiometry and desired conjugation density

Downstream process integration

• Covalent introduction into peptide backbone prior to linker attachment
• Deprotection and conjugation carried out in inert, moisture-controlled reactors
• Purification incorporated via preparative HPLC to prevent residual dichlorobenzyl transfer
• Documentation of in-process control checks for regulatory purposes

Final product types

• Peptide-drug conjugates for targeted therapy clinical trials
• Radio-labeled peptides for preclinical imaging
• Antibody-peptide hybrids for oncology or autoimmune indications
• Investigational new drug (IND) samples